^
    Back
    Association details:
    Biomarker:TPD52L1-ROS1 fusion
    Cancer:Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JTO Clin Res Rep
    Title:

    TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

    Published date:
    02/09/2020
    Excerpt:
    NGS showed EGFR exon21 L858R mutation with newly emerged MET amplification and TPD52L1-ROS1 rearrangement...the patient received the treatment of crizotinib combined with osimertinib…which was found to be effective with substantial decrease of pleural effusion and disappearance of lymph node in the right axilla in two months.
    DOI:
    10.1016/j.jtocrr.2020.100034